• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Should Five Year AMVUTTRA Data Require Action From Alnylam Stock Investors?

    Simply Wall St·11/05/2026 02:47:02
    Listen to the news
    • Alnylam Pharmaceuticals reported Q3 2026 revenue of US$1,458.09m and net income of US$2,167.34m, while highlighting upcoming presentations of extensive long term clinical and real world data for AMVUTTRA in transthyretin amyloidosis.
    • The five year HELIOS B readout and large real world cohorts position AMVUTTRA as a heavily studied RNAi therapy, which matters for payer discussions, treatment positioning and Alnylam’s broader TTR franchise story.
    • The focus now shifts to how Alnylam’s investment narrative around RNAi scale and ATTR durability is affected by the five year HELIOS B dataset.

    Scan how Alnylam Pharmaceuticals fits into the broader RNA and biotech story by comparing it with a curated group of 19 high quality undiscovered gems that may be flying under most investors' radar.

    Alnylam Pharmaceuticals Investment Narrative Recap

    To own Alnylam Pharmaceuticals, you need to be comfortable with a business that leans heavily on the AMVUTTRA TTR franchise today while spending aggressively to push RNAi into broader cardiovascular and neurological uses. The key near term swing factor is AMVUTTRA performance versus payer pressure and prior guidance cuts, because that product still anchors revenue and sentiment.

    The new HELIOS B and real world AMVUTTRA data look important for buttressing that cornerstone, yet they do not remove the main risk. Ongoing net price erosion, potential further adjustments to TTR guidance and high R&D and SG&A needs can still squeeze margins if newer programs like zilebesiran and nucresiran take time to contribute.

    Among the recent updates, the US$1b share repurchase authorization stands out as most relevant to this AMVUTTRA heavy story. It sits alongside Q3 2026 numbers, with quarterly revenue of US$1,458.09m and net income of US$2,167.34m, plus reiterated 2026 total net product revenue guidance of US$4.7b to US$5.1b.

    For you as a shareholder, the buyback ties directly into the catalyst and risk mix. The impact depends on how effectively Alnylam Pharmaceuticals translates its TTR and RNAi data into product demand while working within that revenue guidance range. If AMVUTTRA pricing, payer dynamics or pipeline execution change materially, the same capital return choice may feel less comfortable against future R&D and commercialization needs.

    Alnylam Pharmaceuticals' narrative projects US$8.7b revenue and US$1.9b earnings by 2029. That profile reflects an assumption of 20.0% yearly revenue growth and an earnings decline of US$0.8b from US$2.7b today.

    Uncover why Alnylam Pharmaceuticals' fair value indicates a 106% potential upside to its current price that could narrow quickly.

    NasdaqGS:ALNY 1-Year Stock Price Chart
    NasdaqGS:ALNY 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate angle you might explore is the legal risk tied to Alnylam Pharmaceuticals. The most cautious analysts were already baking in securities investigations, projecting only US$7.0b of revenue and about US$1.2b of earnings by 2029, which is far below consensus. Those views have not yet absorbed today’s new HELIOS B and AMVUTTRA data, so opinions could shift meaningfully from here.

    Explore 4 other Alnylam Pharmaceuticals fair value estimates, including one that suggests it could be worth just $199.00!

    The Verdict Is Yours

    Don't just follow the ticker, dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Alnylam Pharmaceuticals?

    If Alnylam Pharmaceuticals has sharpened your thinking about RNA therapies and risk, use that momentum to broaden your watchlist with other companies that fit clear, data driven criteria.

    • If you want income to play a bigger role in your returns, check out high yield opportunities screened as 5 dividend fortresses and see which payouts look better backed by fundamentals.
    • For investors who care most about capital strength and staying power, start with the list of solid balance sheet and fundamentals (25 results) and focus on businesses that aim to keep financial risk contained.
    • When you are hunting for stocks that the market may not be paying full attention to yet, use the 19 high quality undiscovered gems and see which quieter stories match your risk and return preferences.